Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Mar;12(1):33-34.
doi: 10.17925/EE.2016.12.01.33. Epub 2016 Mar 15.

Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis - Clinical Implications in the Treatment of Patients with Type 2 Diabetes

Kirsten Stinkens  1 , Chantal Mathieu  1
Affiliations
Editorial

Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis - Clinical Implications in the Treatment of Patients with Type 2 Diabetes

Kirsten Stinkens et al. Eur Endocrinol. 2016 Mar.

Abstract

The use of sodium-glucose cotransporter 2 inhibitors is associated with an increased risk of diabetic ketoacidosis. This risk has been reported in particular in off-label use of these agents in type 1 diabetes, but reports of risks in type 2 diabetes patients also exist. In type 2 diabetes ketoacidosis is rare and is present particularly in patients who have undergone prolonged starvation, serious infection, alcohol abuse or surgery. The pleiotropic advantages of sodium-glucose cotransporter 2 inhibitors do not outweigh the risk for a diabetic ketoacidosis, but caution is warranted.

Keywords: Sodium-glucose cotransporter 2 inhibitors; ketoacidosis; type 2 diabetes.

PubMed Disclaimer

References

    1. Monami M., Nardini C., Mannuci E.. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457–66. - PubMed
    1. Yang X. P., Lai D., Zhong X. Y.. et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol. 2014;70:1149–58. - PubMed
    1. Liakos A., Karagiannis T., Athanasiadou E.. et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984–93. - PubMed
    1. Fioretto P., Giaccari A., Sesti G.. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. 142Cardiovasc Diabetol. 2015;14 - PMC - PubMed
    1. Stanton C.. Sodium glucose transport 2 inhibition decrease glomerular hyperfiltration. Circulation. 2014;129:542–44. - PubMed

Publication types

LinkOut - more resources